Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

“Regeneron’s financial and commercial strength allows for ... Click now to get top trade ideas daily, plus unlimited access ...

(RTTNews) - Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with Regeneron Pharmaceuticals. The supply agreement supports ...

Moving to our Regeneron genetics medicine pipeline. Starting with our differentiated siRNA plus antibody approach, we have the potential to address multiple complement mediated diseases.

Regeneron also proffered selected guidance for ... but it is a good mix of established and up-and-coming products, plus it's doing well with collaborations and has a robust pipeline.

We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...